1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Ziritaxestat Failure Could Spell End For Gilead/Galapagos Pact

IPF And Systemic Sclerosis Trials Abandoned

 
• By Kevin Grogan

The Galapagos and Gilead partnership has had a tough few months and the failure of ziritaxestat, plus the decision not to develop filgotinib Stateside for rheumatoid arthritis, is calling into question the merits of the whole collaboration for the US biotech.

split up
Testing times for the Galapagos and Gilead partnership • Source: Shutterstock

The multi-billion dollar R&D alliance inked by Gilead Sciences, Inc. and Galapagos NV was seen as a model partnership in the pharma industry but another late-stage disappointment, this time for the fibrotic disease candidate ziritaxestat, has left the relationship hanging by a thread.

Galapagos has announced that it is halting the ISABELA Phase III program for ziritaxestat which involved two identically designed studies that combined were expected to enroll about 1,500 idiopathic pulmonary fibrosis (IPF) patients

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.